Targeting Brain Tumors with Nanomedicines: Overcoming Challenges of Blood Brain Barrier.

Targeting Brain Tumors with Nanomedicines: Overcoming Challenges of Blood Brain Barrier.
Curr Clin Pharmacol. 2018 Apr 12;:
Authors: Ningaraj NS, Reddy PL, Khaitan D
Abstract
This review elucidates ongoing research, which show improved delivery of anticancer drugs alone and/ or enclosed in carriers collectively called nanomedicines to cross the Blood brain barrier (BBB) / blood-brain tumor barrier (BTB) to kill tumor cells and impact patient survival. We highlighted various advances in understanding the mechanism of BTB function that impact on anticancer therapeutics delivery. We discussed latest breakthroughs in developing pharmaceutical strategies, including nanomedicines and delivering them across BTB for brain tumor management and treatment. We highlight various studies on regulation of BTB permeability regulation with respect to nanotech-based nanomedicines for targeted treatment of brain tumors. We have reviewed latest literature on development of specialized molecules and nanospheres for carrying pay load of anticancer agents to brain tumor cells across the BBB/ BTB and avoid drug efflux systems. We discuss identification and development of distinctive BTB biomarkers for targeted anti-cancer drug delivery to brain tumors. In addition, we discussed nanomedicines and multimeric molecular therapeutics that were encapsulated in nanospheres for treatment and monitoring of brain tumors. In this context, we highlight our research on ...

Source: Current Clinical Pharmacology - April 12, 2018 Category: Drugs & Pharmacology Authors: Ningaraj NS, Reddy PL, Khaitan D Tags: Curr Clin Pharmacol Source Type: research